GlassScriptPhysician profile
Ronald Pham
NPI 1629509591
$3,280.38
in general payments reported to CMS, 2019-2025
30 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $156 · 2021: $618 · 2022: $97.20 · 2023: $414 · 2024: $833 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.89 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $467.37 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Inari Medical, INC. | $395.49 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amgen INC. | $387.57 | 2020-2025 | Repatha, Otezla, Repatha |
| Viiv Healthcare Company | $370.28 | 2024-2025 | Apretude |
| Lilly USA, LLC | $269.86 | 2021-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $196.65 | 2021-2025 | |
| Dexcom, INC. | $171.75 | 2024-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $144.30 | 2025 | Yeztugo |
| Boston Scientific Corporation | $124.99 | 2020 | |
| Merck Sharp & Dohme LLC | $100.32 | 2021-2025 | Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $85.57 | 2020-2025 | Breztri, Airsupra |
| Astellas Pharma US INC | $62.59 | 2024 | Veozah |
| Optinose US, INC. | $52.57 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $51.09 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $45.41 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $42.96 | 2021 | |
| Pfizer INC. | $39.30 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $32.67 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $32.06 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.99 | 2022 | |
| Shield Therapeutics INC | $24.56 | 2024 | |
| Exact Sciences Corporation | $24.32 | 2023 | Cologuard Collection Kit |
| Acella Pharmaceuticals, LLC | $20.19 | 2024 | NP Thyroid 60 |
| Glaxosmithkline, LLC. | $19.76 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.74 | 2021 | |
| Eisai INC. | $17.48 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.81 | 2021 | |
| Sandoz INC. | $15.52 | 2023 | Hyrimoz |
| Kowa Pharmaceuticals America, INC. | $14.51 | 2021 | |
| Amneal Pharmaceuticals LLC | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.